Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.
20h
Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...
which is nearing initiation of Phase 2 clinical trial in patients with moderate-to-severe rheumatoid arthritis, and a Phase 2a clinical trial for an additional autoimmune indication. Uvax Bio ...
Island Pharmaceuticals Ltd ( ($AU:ILA) ) has issued an announcement. Island Pharmaceuticals Ltd has progressed significantly in its ISLA-101 Phase ...
Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...
In a phase 1b/2a trial subcutaneous amycretin demonstrated a safety profile similar to other incretin-based drugs . Adults ...
Novo Nordisk (NVO) announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist ...
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback